Ranolazine-d8 (CVT 303-d8) is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inwardsodiumcurrent (I_NaandI_KrwithIC₅₀values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)^[1][2]. Ranolazine is also a partialfatty acid oxidation (FAO)inhibitor^[3]. Antianginal agent.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

435.59

C₂₄H₂₅D₈N₃O₄

1092804-88-0

雷诺嗪 d8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.